TeneoBio, Inc.
1490 O’Brien Drive
Suite D
Menlo Park
California
94025
United States
Tel: 650-899-8200
Website: https://www.teneobio.com/
Email: busdev@teneobio.com
About TeneoBio, Inc.
TeneoBio, Inc. is a biotechnology company that is developing a new class of biologics, Human Heavy Chain Antibodies (UniAbs™), as therapeutics against cancer, autoimmunity, and infectious diseases. TeneoBio has several products in pre-clinical development for the treatment of multiple myeloma, prostate cancer, immune disorders and AIDS.
LEADERSHIP:
CEO: Roland Buelow
CFO: Stephen Dance
CMO: Ben Buelow
CSO: Wim van Schooten
CBO: Omid Vafa
6 articles with TeneoBio, Inc.
-
Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies
1/8/2018
TESARO will have exclusive licenses to the antibodies for clinical development and commercialization on a global basis.
-
TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology
12/11/2017
Data showed results from the application of TeneoBio’s suite of technologies in the generation of the lead therapeutic candidate.
-
Selexis SA And TeneoBio, Inc.Team Up To Advance The Development Of Uniabs Targeting Cancer
6/12/2017
-
TeneoBio, Inc. And Poseida Therapeutics Announce License Agreement For The Use Of Unidab In CAR T-Cell Therapy
5/22/2017
-
TeneoBio, Inc.’s Next Generation T Cell Redirection Antibody Platform For Cancer Biotherapeutics Offers Prospects Of Reducing Cytokine Release
5/1/2017
-
TeneoBio, Inc.’s Next Generation T Cell Redirection Antibody Platform For Cancer Biotherapeutics
5/1/2017